Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Shares Outstanding (Weighted Average) (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $14.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 462.02% year-over-year to $14.0 million, compared with a TTM value of $14.0 million through Sep 2025, up 462.02%, and an annual FY2018 reading of $34.8 million, up 88.88% over the prior year.
  • Shares Outstanding (Weighted Average) was $14.0 million for Q3 2025 at Avalo Therapeutics, up from $10.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $14.0 million in Q3 2025 and bottomed at $859381.0 in Q1 2024.